<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02408484</url>
  </required_header>
  <id_info>
    <org_study_id>FORMA-04</org_study_id>
    <nct_id>NCT02408484</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Deficiency</brief_title>
  <official_title>Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Paediatric Subjects With Congenital Fibrinogen Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Octapharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the efficacy of Octafibrin, a fibrinogen concentrate in in the
      on-demand treatment of spontaneous or traumatic bleeding episodes in paediatric patients less
      than 12 years of age.The planned study duration is up to 5 years. The study will be
      considered completed when a minimum of 6 subjects (i.e., at least 3 subjects aged between 0
      and &lt;6 years and 3 subjects aged between 6 and &lt;12 years) have at least one documented
      bleeding episode and when in total a minimum of 2 surgical procedures have been performed.

      All patients will undergo a pharmacokinetic (PK) study after screening. This will have a
      duration of 14 days, after which a patient can be treated for a bleeding episode or planned
      surgical procedure when they occur.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall clinical assessment of the haemostatic efficacy of Octafibrin in treating the first documented bleeding episode of each patient</measure>
    <time_frame>First Octafibrin infusion for the treatment of a bleeding episode until 24 hours (i.e., 1 day) after the last infusion or the end of the treatment observation period, whichever comes last</time_frame>
    <description>The investigator's overall clinical assessment of haemostatic efficacy for bleeding will be based on a 4-point haemostatic efficacy scale. The final efficacy assessment of each patient will be adjudicated by the Independent Data Monitoring &amp; Endpoint Adjudication Committee (IDMEAC). The number of subjects per outcome category will be assessed in the final analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single-dose pharmacokinetics of Octafibrin: Area under the concentration-time curve (AUC)</measure>
    <time_frame>Before first infusion to 14 days post-infusion</time_frame>
    <description>AUC will be assessed after a single intravenous infusion of 70 mg/kg body weight of Octafibrin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose pharmacokinetics of Octafibrin: Response - Incremental in vivo recovery (IVR)</measure>
    <time_frame>Before first infusion to 14 days post-infusion</time_frame>
    <description>IVR will be assessed after a single intravenous infusion of 70 mg/kg body weight of Octafibrin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose pharmacokinetics of Octafibrin: Classical incremental in vivo recovery (IVR)</measure>
    <time_frame>Before first infusion to 14 days post-infusion</time_frame>
    <description>Classical IVR will be assessed after a single intravenous infusion of 70 mg/kg body weight of Octafibrin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose pharmacokinetics of Octafibrin: Terminal elimination half-life (t1/2)</measure>
    <time_frame>Before first infusion to 14 days post-infusion</time_frame>
    <description>t1/2 will be assessed after a single intravenous infusion of 70 mg/kg body weight of Octafibrin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose pharmacokinetics of Octafibrin: Maximum plasma concentration (Cmax)</measure>
    <time_frame>Before first infusion to 14 days post-infusion</time_frame>
    <description>Cmax will be assessed after a single intravenous infusion of 70 mg/kg body weight of Octafibrin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose pharmacokinetics of Octafibrin: Time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>Before first infusion to 14 days post-infusion</time_frame>
    <description>Tmax will be assessed after a single intravenous infusion of 70 mg/kg body weight of Octafibrin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose pharmacokinetics of Octafibrin: Mean residence time (MRT)</measure>
    <time_frame>Before first infusion to 14 days post-infusion</time_frame>
    <description>MRT will be assessed after a single intravenous infusion of 70 mg/kg body weight of Octafibrin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose pharmacokinetics of Octafibrin: Volume of distribution (Vss)</measure>
    <time_frame>Before first infusion to 14 days post-infusion</time_frame>
    <description>Vss will be assessed after a single intravenous infusion of 70 mg/kg body weight of Octafibrin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose pharmacokinetics of Octafibrin: Clearance (Cl)</measure>
    <time_frame>Before first infusion to 14 days post-infusion</time_frame>
    <description>Cl will be assessed after a single intravenous infusion of 70 mg/kg body weight of Octafibrin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum clot firmness (MCF) before and following first infusion of each documented bleeding episode</measure>
    <time_frame>Before first infusion and 1 hour after end of first infusion of each documented bleeding episode</time_frame>
    <description>MCF will be determined using thromboelastometry (ROTEM) and will be used as a surrogate marker for haemostatic efficacy. ROTEM is a method for the continuous measurement of clot formation and clot firmness. It utilises a mechanical detection system which is based on the ability of the blood or plasma clot to form a mechanical coupling over a distance of 1 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen plasma level</measure>
    <time_frame>Before and 1 hour after the end of each infusion as well as at the time of the overall clinical assessment of haemostatic efficacy (i.e., 24 hours after the last infusion or end of the observation period of each documented bleeding episode)</time_frame>
    <description>Fibrinogen plasma level will be assessed using the Clauss fibrinogen assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response after the first infusion of each bleeding episode as indicated by incremental in vivo recovery</measure>
    <time_frame>Pre-infusion and 3 hours post-infusion</time_frame>
    <description>Incremental IVR calculated as the maximum increase in plasma fibrinogen (Clauss data) between the pre-infusion and the 3-hour post-infusion measurement, divided by the exact dose of Octafibrin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Octafibrin in all bleeding episodes</measure>
    <time_frame>First Octafibrin infusion for the treatment of a bleeding episode until 24 hours (i.e., 1 day) after the last infusion or the end of the treatment observation period, whichever comes last</time_frame>
    <description>The investigator's overall clinical assessment of haemostatic efficacy for bleeding will be based on a 4-point haemostatic efficacy scale. The final efficacy assessment of each patient will be adjudicated by the Independent Data Monitoring &amp; Endpoint Adjudication Committee (IDMEAC). The number of subjects per outcome category will be assessed in the final analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Octafibrin in surgical prophylaxis</measure>
    <time_frame>First dose of Octafibrin prior to elective surgery, to at least 3 post-operative days for minor and 7 post-operative days for major surgeries or until the day of the last post-operative infusion, whichever comes last</time_frame>
    <description>Efficacy of Octafibrin will be assessed at the end of surgery by the surgeon and post-operatively by the haematologist using two four-point scales. An overall efficacy assessment taking both the intra- and post-operative assessment into account will be adjudicated by the IDMEAC. The final endpoint determination will be based on the adjudicated assessments using an agreed algorithm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment: Thromboembolic event (TEE) questionnaire</measure>
    <time_frame>Start of the first Octafibrin infusion to the end of PK, end of 30-day observation and follow-up period for on-demand treatment, or the end of the surgical observation period</time_frame>
    <description>TEE questionnaire completed at all study visits for the treatment of bleeding episodes and for surgeries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment: Adverse events</measure>
    <time_frame>Start of the first Octafibrin infusion to the end of PK, end of 30-day observation and follow-up period for on-demand treatment, or the end of the surgical observation period</time_frame>
    <description>Adverse events, including thromboembolic complications and early signs of allergic or hypersensitivity reactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment: Immunogenicity testing for anti-fibrinogen antibodies</measure>
    <time_frame>Start of the first Octafibrin infusion to the end of each 30-day observation and follow-up period for on-demand treatment</time_frame>
    <description>Immunogenicity testing for the presence of anti-fibrinogen antibodies before the first infusion of Octafibrin and on Day 30 after the treatment of each bleeding episode.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Congenital Fibrinogen Deficiency</condition>
  <arm_group>
    <arm_group_label>Octafibrin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasma-derived fibrinogen concentrate</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Octafibrin</intervention_name>
    <description>Plasma-derived Fibrinogen concentrate</description>
    <arm_group_label>Octafibrin</arm_group_label>
    <other_name>Fibrinogen concentrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged &lt;12 years (at the start of treatment).

          -  Documented diagnosis of congenital fibrinogen deficiency, expected to require
             on-demand treatment for bleeding or surgical prophylaxis:

               -  Fibrinogen deficiency manifested as afibrinogenaemia or severe
                  hypofibrino-genaemia.

               -  Historical plasma fibrinogen activity of &lt;50 mg/dL or levels below the limit of
                  detection of the local assay method.

          -  Expected to have an acute bleeding episode (spontaneous or after trauma) or planning
             to undergo elective surgery.

          -  Informed consent signed by the subject's legal guardian.

        Exclusion Criteria:

          1. Life expectancy &lt;6 months.

          2. Bleeding disorder other than congenital fibrinogen deficiency, including
             dysfi-brinogenaemia.

          3. Prophylactic treatment with a fibrinogen concentrate.

          4. Treatment with:

               -  Any fibrinogen concentrate or other fibrinogen-containing blood product within 2
                  weeks prior to start of treatment for the PK phase, a bleeding episode, or
                  surgery.

               -  Any coagulation-active drug (i.e., non-steroidal anti-inflammatory drugs,
                  war-farin, coumarin derivatives, platelet aggregation inhibitors) within 1 week
                  prior to start of the PK phase or treatment for the bleeding episode or surgery,
                  or as a planned or expected medication during the time period from Day 1 until 24
                  hours (i.e., 1 day) after the last Octafibrin infusion.

          5. Presence or history of:

               -  Hypersensitivity to study medication.

               -  Deep vein thrombosis or pulmonary embolism within 1 year prior to start of
                  treatment for the bleeding episode or surgery.

               -  Arterial thrombosis within 1 year prior to start of treatment for the bleeding
                  episode or surgery

               -  Hypersensitivity to human plasma proteins.

               -  Oesophageal varicose bleeding.

               -  End-stage liver disease (i.e., Child-Pugh score B or C).

          6. Known positive HIV infection with a viral load &gt;200 particles/Î¼L or &gt;400,000
             copies/mL.

          7. Polytrauma 1 year prior to start of treatment for the bleeding episode or surgery.

          8. Diagnosis or suspicion of a neutralizing anti-fibrinogen inhibitor currently or any
             time in the past.

          9. Acute or chronic medical condition which may, in the opinion of investigator, affect
             the conduct of the study, including subjects receiving immune-modulating drugs (other
             than anti-retroviral chemotherapy), such as alpha-interferon, predni-sone (equivalent
             to &gt;10 mg/day), or similar drugs, at study start.

         10. Treatment with IMP in another interventional clinical study currently or during the
             past 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Solomon, MD</last_name>
    <role>Study Director</role>
    <affiliation>Octapharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristina Solomon, MD</last_name>
    <phone>+41554512189</phone>
    <email>cristina.solomon@octapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. John's Medical College Hospital</name>
      <address>
        <city>Bangalore</city>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>S.S Institute of Medical Science and Research Center</name>
      <address>
        <city>Davangere</city>
        <zip>577005</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sahyadri Specialty Hospital</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Nemazee Hospital Shiraz University of Medical Sciences</name>
      <address>
        <city>Shiraz</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hotel De Dieu de France</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
    <country>Iran, Islamic Republic of</country>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2015</study_first_submitted>
  <study_first_submitted_qc>April 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2015</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afibrinogenemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

